Rayner’s RayOne EMV IOL Approved By FDA
Since producing the first IOL in the world in 1949, Rayner has led the way in innovation, focusing on giving you and your patients the best IOLs and opthalmic solutions while always being guided by research to enhance patient outcomes and safety. The South Coast of England is home to Rayner's cutting-edge manufacturing facility and global headquarters, making it the only IOL maker in the UK. 26 March 2021, New York, USA - The FDA has approved Rayner's RayOne EMV, a novel fully preloaded non-diffractive IOL. The Australasian Society of Cataract & Refractive Surgeons' president, Professor Graham Barrett, a well regarded surgeon, helped create RayOne EMV.
“I collaborated with Rayner on bringing to market RayOne EMV, an exciting new product for all surgeons,” said Professor Barrett.
Initial Clinical Results
Dr. Mariano Royo, Director of Ophthalmology at the Hospital San Rafael in Madrid and President of the Madrid Ophthalmic Institute, presented the clinical outcomes of 22 RayOne EMV-implanted eyes from 11 patients, measured six months after surgery. 100% of Dr. Royo's patients who underwent RayOne EMV were able to see without glasses at a distance and in an intermediate range. According to reports, the average reading assistance at 33 cm was +1.5 D, and one in three patients had usable near vision without the need for glasses.
What Does This Mean for Surgeons?
Patients can use RayOne EMV as a cost-effective alternative when diffractive IOLs may be too expensive or if dysphotopsia issues are present.
"Since our RayOne and RayPRO platforms were approved in 2019, we have been progressively increasing our investment there to make it one of our most significant markets globally. According to Tim Clover, CEO of Rayner, "the clearance of RayOne EMV is significant because it enables surgeons to offer patients a novel option that has been proven and tested in thousands of patients throughout the world.
RayPRO, a free contactless telemedicine service that gathers three years' worth of patient reported results following cataract or refractive surgery, can be used to track patient outcomes for RayOne EMV.
About Rayner
Rayner creates and produces intraocular lenses (IOLs) and other ophthalmic products for use throughout the clinical route for cataract patients. The world's first intraocular lens was created by Rayner in collaboration with Sir Harold Ridley and implanted in a patient on November 29, 1949, at the St. Thomas Hospital in London, United Kingdom.
We have been growing and learning for more than 70 years, and we continue to be at the cutting edge of innovation. In order to increase performance and safety, we are committed to giving doctors and patients the greatest visual results possible. For their RayOne preloaded injector, Rayner won the Queen's Award for Enterprise in the area of Innovation in 2020.
With its global headquarters in Worthing, England, Rayner sells its goods through a network of distributors as well as direct sales offices in countries like the UK, the USA, Germany, Austria, Italy, Spain, Portugal, and Russia.
